Following FDA Registration of Facility, Agilent Stays Mum on Dx Plans

A company official shed little light on Agilent's plans for the diagnostics space, but an investment analyst said that the company will probably remain a peripheral player.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.